Close Menu

Danaher

Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.

The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.

Life Science and Diagnostics sales grew almost 15 percent year over year, helped by the purchase of Pall. 

Net proceeds from the offering are expected to be $1.98 billion, which will be used to repay part of the financing that went toward Danaher's buy of Pall.

Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies. 

CEO Thomas Joyce said that the company's pending $13.8 billion buy of Pall has received US regulatory approval and an EU decision is expected next month. 

The company replaced an existing $2.5 billion facility with an amended and restated $4 billion facility and entered into a new $7 billion facility.

Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.

The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.

Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.